1. Fluorescence Imaging for Cancer Screening and Surveillance
- Author
-
A. D. Haskins, William R. Carroll, Kiranya E. Tipirneni, Jason M. Warram, Lindsay S. Moore, Jianghong Rao, Aditi Jani, Neha Udayakumar, Matthew Bogyo, Anthony B. Morlandt, and Eben L. Rosenthal
- Subjects
Diagnostic Imaging ,Cancer Research ,medicine.medical_specialty ,Fluorescence-lifetime imaging microscopy ,Physical examination ,Fluorescence ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Cancer screening ,Medical imaging ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Stage (cooking) ,Intensive care medicine ,Early Detection of Cancer ,Clinical Trials as Topic ,medicine.diagnostic_test ,business.industry ,Cancer ,medicine.disease ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,Population Surveillance ,030211 gastroenterology & hepatology ,Molecular imaging ,business - Abstract
The advent of fluorescence imaging (FI) for cancer cell detection in the field of oncology is promising for both cancer screening and surgical resection. Particularly, FI in cancer screening and surveillance is actively being evaluated in many new clinical trials with over 30 listed on Clinical Trials.gov . While surgical resection forms the foundation of many oncologic treatments, early detection is the cornerstone for improving outcomes and reducing cancer-related morbidity and mortality. The applications of FI are twofold as it can be applied to high-risk patients in addition to those undergoing active surveillance. This technology has the promise of highlighting lesions not readily detected by conventional imaging or physical examination, allowing disease detection at an earlier stage of development. Additionally, there is a persistent need for innovative, cost-effective imaging modalities to ameliorate healthcare disparities and the global burden of cancer worldwide. In this review, we outline the current utility of FI for screening and detection in a range of cancer types.
- Published
- 2017